Moneycontrol PRO

HomeNewsSolara active pharma science

Solara Active Pharma Science

Jump to

Solara Active Pharma Science gains on board nod to raising up to Rs 450 crore

Solara Active Pharma Science plans to issue equity shares with a face value of Rs 10 each, totalling up to Rs 450 crore, including premium
JB Chemicals, Solara Active, Strides tank 6-10% as USFDA requests withdrawal of Ranitidine

Ranitidine is an Rx and OTC drug used as an H2 (histamine-2) receptor blocker, which decreases the amount of acid created by the stomach.
3-Point Analysis | Solara posts strong operating profit in Q1 FY20

Moneycontrol's Shraddha Sharma does a 3-Point Analysis of the company's Q1 numbers.
Solara Active Pharma Science jumps 10% on zero observations for Chennai unit

Solara Research Centre was earlier inspected by USFDA as control testing laboratory in December 2012 and August 2016.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347